NO20014131L - Epitoper eller mimotoper avledet fra C-epsilon-3- eller C- epsilon-4-domener fra IgE, antagonister derav og deresterapeutiske anvendelser - Google Patents

Epitoper eller mimotoper avledet fra C-epsilon-3- eller C- epsilon-4-domener fra IgE, antagonister derav og deresterapeutiske anvendelser

Info

Publication number
NO20014131L
NO20014131L NO20014131A NO20014131A NO20014131L NO 20014131 L NO20014131 L NO 20014131L NO 20014131 A NO20014131 A NO 20014131A NO 20014131 A NO20014131 A NO 20014131A NO 20014131 L NO20014131 L NO 20014131L
Authority
NO
Norway
Prior art keywords
epsilon
ige
epitopes
domains
derester
Prior art date
Application number
NO20014131A
Other languages
English (en)
Other versions
NO20014131D0 (no
Inventor
Martin Friede
Sean Mason
William Gordon Turnell
Marcelle Paulette Van Mechelen
Carlota Vinals Y De Bassols
Original Assignee
Peptide Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9904408.3A external-priority patent/GB9904408D0/en
Priority claimed from GBGB9917144.9A external-priority patent/GB9917144D0/en
Priority claimed from GBGB9918598.5A external-priority patent/GB9918598D0/en
Priority claimed from GBGB9918601.7A external-priority patent/GB9918601D0/en
Priority claimed from GBGB9918604.1A external-priority patent/GB9918604D0/en
Priority claimed from GBGB9918606.6A external-priority patent/GB9918606D0/en
Priority claimed from GBGB9918599.3A external-priority patent/GB9918599D0/en
Priority claimed from GBGB9925618.2A external-priority patent/GB9925618D0/en
Application filed by Peptide Therapeutics Ltd filed Critical Peptide Therapeutics Ltd
Publication of NO20014131D0 publication Critical patent/NO20014131D0/no
Publication of NO20014131L publication Critical patent/NO20014131L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Foreliggende oppfinnelse vedrører nye medikamenter for behandling, forebygging og forbedring av allergisk sykdom. Spesielt er de nye medikamentene epitoper eller mimo-toper avledet fra Ce3- eller Ce4-domenene til IgE. Disse nye regionene kan være mål for både passiv og aktiv immunprofylakse eller immunterapi. Oppfinnelsen vedrører ytterligere fremgangsmåter for produksjon av medikamenter, farmasøytisk sammenset-ning inneholdende disse og deres anvendelse i medisin. Også et aspekt for foreliggende oppfinnelse er ligander, spesielt monoklonale antistoffer, som er istand til å binde til IgE-regionene i den foreliggende oppfinnelsen, og deres anvendelse i medisin som passiv immunterapi eller immunprofylakse.
NO20014131A 1999-02-25 2001-08-24 Epitoper eller mimotoper avledet fra C-epsilon-3- eller C- epsilon-4-domener fra IgE, antagonister derav og deresterapeutiske anvendelser NO20014131L (no)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GBGB9904408.3A GB9904408D0 (en) 1999-02-25 1999-02-25 Vaccine
GBGB9917144.9A GB9917144D0 (en) 1999-07-21 1999-07-21 Vaccine
GBGB9918598.5A GB9918598D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9918601.7A GB9918601D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9918604.1A GB9918604D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9918606.6A GB9918606D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9918599.3A GB9918599D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9925618.2A GB9925618D0 (en) 1999-10-29 1999-10-29 Vaccine
PCT/EP2000/001456 WO2000050461A1 (en) 1999-02-25 2000-02-22 Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses

Publications (2)

Publication Number Publication Date
NO20014131D0 NO20014131D0 (no) 2001-08-24
NO20014131L true NO20014131L (no) 2001-10-02

Family

ID=27571340

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20014131A NO20014131L (no) 1999-02-25 2001-08-24 Epitoper eller mimotoper avledet fra C-epsilon-3- eller C- epsilon-4-domener fra IgE, antagonister derav og deresterapeutiske anvendelser

Country Status (18)

Country Link
EP (1) EP1155038A1 (no)
JP (1) JP2002537403A (no)
KR (1) KR20020007314A (no)
CN (1) CN1520423A (no)
AR (1) AR029619A1 (no)
AU (1) AU3281100A (no)
CA (1) CA2363641A1 (no)
CO (1) CO5231139A1 (no)
CZ (1) CZ20013081A3 (no)
HK (1) HK1043134A1 (no)
HU (1) HUP0105490A3 (no)
IL (1) IL145025A0 (no)
MX (1) MXPA01008612A (no)
NO (1) NO20014131L (no)
NZ (1) NZ513680A (no)
PL (1) PL350992A1 (no)
TR (1) TR200102493T2 (no)
WO (1) WO2000050461A1 (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001045745A2 (en) * 1999-12-21 2001-06-28 Acambis Research Limited A reversible linkage technology for controlled conjugation
WO2001085208A2 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
GB0026334D0 (en) * 2000-10-27 2000-12-13 Smithkline Beecham Biolog Vaccine
US7320793B2 (en) * 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
JP2003047482A (ja) * 2001-05-22 2003-02-18 Pfizer Prod Inc 非アナフィラキシー誘発性ＩｇＥワクチン
EP1450856B1 (en) 2001-09-14 2009-11-11 Cytos Biotechnology AG Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
GB0209878D0 (en) * 2002-04-30 2002-06-05 Glaxosmithkline Biolog Sa Vaccine
JP4726483B2 (ja) 2002-07-17 2011-07-20 サイトス バイオテクノロジー アーゲー 分子抗原アレイ
KR101228376B1 (ko) 2002-07-18 2013-01-31 사이토스 바이오테크놀로지 아게 합텐-캐리어 컨쥬게이트 및 그의 용도
DE60336902D1 (de) 2002-07-19 2011-06-09 Cytos Biotechnology Ag Impfstoffzusammensetzungen enthaltende amyloid beta 1-6 antigenarrays
WO2005075504A1 (en) * 2004-02-02 2005-08-18 Tanox, Inc. IDENTIFICATION OF NOVEL IgE EPITOPES
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
RU2351362C2 (ru) 2003-03-26 2009-04-10 Цитос Байотекнолоджи Аг КОНЪЮГАТЫ ПЕПТИДА Melan-A, АНАЛОГА ВИРУСОПОДОБНОЙ ЧАСТИЦЫ
GB0424563D0 (en) 2004-11-05 2004-12-08 Novartis Ag Organic compounds
EP1941275B1 (en) 2005-09-29 2013-07-24 Medimmune, Inc. Method of identifying membrane lg specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells
WO2007068747A1 (en) 2005-12-14 2007-06-21 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
JP5437797B2 (ja) 2006-06-12 2014-03-12 サイトス バイオテクノロジー アーゲー Ｒｎａバクテリオファージのウイルス様粒子にオリゴヌクレオチドをパッケージ化するための方法
MX337723B (es) * 2008-12-09 2016-03-15 Pfizer Vaccines Llc Vacuna de peptido ch3 de ige.
EP2942061A3 (en) 2010-06-07 2016-01-13 Pfizer Vaccines LLC Ige ch3 peptide vaccine
US9657071B2 (en) * 2012-06-18 2017-05-23 Nippon Zenyaku Kogyo Co., Ltd. IgE peptide vaccine
AU2019247321A1 (en) * 2018-04-06 2020-10-22 Slsbio Co., Ltd. Novel epitope of immunoglobulin E, antibody binding thereto, and kit for analyzing immunoglobulin E in sample containing same
US20240245190A1 (en) 2023-01-19 2024-07-25 Sharkninja Operating Llc Identification of hair care appliance attachments
EP4651762A1 (en) 2023-01-19 2025-11-26 SharkNinja Operating LLC Hair care appliance with powered attachment
WO2025100514A1 (ja) * 2023-11-09 2025-05-15 株式会社ファンペップ 抗ＩｇＥ抗体誘導用ワクチン組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02229200A (ja) * 1989-02-28 1990-09-11 Dainippon Pharmaceut Co Ltd 抗アレルギー作用を有するペプチド
DK0602126T3 (da) * 1991-08-14 2003-06-16 Genentech Inc Immunoglobulinvarianter til specifikke FC epsilon-receptorer
CA2245497C (en) * 1996-03-01 2009-02-24 Novartis Ag Peptide immunogens for vaccination against and treatment of allergy
WO1998024808A2 (en) * 1996-12-06 1998-06-11 THE UNITED STATES OF AMERICA represented by THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES, THE NATIONAL INSTITUTES OF HEALTH INHIBITION OF IgE-MEDIATED ALLERGIES BY A HUMAN IgE-DERIVED OLIGOPEPTIDE
TWI227241B (en) * 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate

Also Published As

Publication number Publication date
JP2002537403A (ja) 2002-11-05
MXPA01008612A (es) 2003-06-24
KR20020007314A (ko) 2002-01-26
CO5231139A1 (es) 2002-12-27
AR029619A1 (es) 2003-07-10
HUP0105490A2 (hu) 2002-04-29
EP1155038A1 (en) 2001-11-21
PL350992A1 (en) 2003-02-24
CA2363641A1 (en) 2000-08-31
IL145025A0 (en) 2002-06-30
AU3281100A (en) 2000-09-14
CZ20013081A3 (cs) 2002-02-13
WO2000050461A1 (en) 2000-08-31
HUP0105490A3 (en) 2002-05-28
NO20014131D0 (no) 2001-08-24
HK1043134A1 (zh) 2002-09-06
CN1520423A (zh) 2004-08-11
TR200102493T2 (tr) 2002-02-21
NZ513680A (en) 2001-09-28

Similar Documents

Publication Publication Date Title
MXPA01008612A (es) Epitopos o mimotopos derivados de los dominos c-epsilon-3 o c-epsilon-4 de ige, antagonistas de los mismos y sus usos terapeuticos.
NO20053920L (no) Preparat for og behandling av demyelineringssykdommer og paralyse ved administrering av remyelineringsmidler.
DE60028970D1 (de) An her2 bindende peptidverbindungen
ATE409181T1 (de) Proteomimetische verbindungen und verfahren
MA31899B1 (fr) Anticorps monoclonaux qui se lient au hgm-csf et compositions medicales les comprenant
UA90457C2 (ru) Человеческое моноклональное антитело, которое специфически связывается с м-csf человека и блокирует связывание м-csf с с-fms
WO2006002177A3 (en) Interferon alpha receptor 1 antibodies and their uses
GEP20084484B (en) Antibodies to insulin-like growth factor i receptor
EA201100546A1 (ru) Полипептиды, вариабельные домены антител и антагонисты
BRPI0407058A (pt) Métodos de profilaxia e de tratamento de uma doença, composição farmacêutica, e, uso de um fragmento
CY1112376T1 (el) Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2
EP3854875A4 (en) HUMAN MONOCLONAL ANTIBODY SPECIFIC BINDING TO HUMAN HMGB1 AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF ALZHEIMER'S DISEASE CONTAINING THE HUMAN MONOCLONAL ANTIBODY
BR0314797A (pt) Derivados da pirimidineamida e o uso dos mesmos
Zinkhan et al. On the role of allergen-specific IgG subclasses for blocking human basophil activation
MXPA03011499A (es) Proteinas de fusion de fce para el tratamiento de alergia y asma.
AU6819600A (en) Use of cd28 specific monoclonal antibodies for producing a pharmaceutical composition for treating virus infections
MX2009003039A (es) Utilizacion de un anticuerpo anti-cd151 para el tratamiento del cancer.
ATE235551T1 (de) Ligand (tie ligand-4) vom tie-2 rezeptor und dessen verwendungen
MXPA01008613A (es) Epitopos o mimotopos derivados del dominio c-epsilon-2 de ige, antagonistas de los mismos y sus usos terapeuticos.
WO2002034288A8 (en) Vaccine for treating allergy
WO2004110355A3 (en) Compositions and methods including a recombinant human mab that promotes cns remyelination
DK1492539T3 (da) Statin-terapi til forögelse af kognitiv funktion
EA200702634A1 (ru) Гуманизированные антитела, специфичные в отношении nogo-a, и их фармацевтические применения
ATE378068T1 (de) Kombination von verbindungen, welche die biologischen wirkungen von tnf-alpha und cd95l hemmen, in einem arzneimittel
ATE298244T1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf- erkrankungen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application